Has Felix Davelman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $392 in general payments to Felix Davelman, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Felix Davelman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Felix Davelman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Felix Davelman, MD

Urology · Middletown, NYNPI 1023276730

Payments from drug & device makers

$392in general payments, 2019–2025

Across 14 payments — averaging $28.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teleflex LLC$175
Medtronic$97
Boston Scientific$46
AstraZeneca$35
Sumitomo Pharma America, Inc.$25
Cook Medical LLC$14

What the payments were for

Food & beverage$35791%
Education$359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teleflex LLC	2	$175
Medtronic(2 entities)	7	$97
Boston Scientific	2	$46
AstraZeneca	1	$35
Sumitomo Pharma America, Inc.	1	$25
Cook Medical LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Barrigel$158

How this compares

$392 in reported general payments places this provider in the 20th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024

$326,461

Medicare patients

1,018

Services billed

6,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	150	$116,687
GemtesaVibegron	89	$82,055
Tolterodine Tartrate ErTolterodine Tartrate	265	$30,287
Tamsulosin Hcl	1,886	$27,673
Oxybutynin Chloride ErOxybutynin Chloride	905	$22,809
Solifenacin Succinate	131	$7,193
NitrofurantoinNitrofurantoin Macrocrystal	124	$5,862
Finasteride	467	$5,827
Alfuzosin Hcl ErAlfuzosin Hcl	220	$5,818
Testosterone	16	$5,667
Tadalafil	13	$2,316
Estradiol	31	$2,290
Desmopressin Acetate	45	$1,629
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	48	$1,236
Oxybutynin Chloride	49	$999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa	$25	$82,05589 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 952 urology providers in New York.

Other urology in Middletown

Steven RoweMiddletown$200K
Christopher PieczonkaSyracuse$31.2M
Guarionex DecastroNew York$5.7M
Mitchell EfrosGarden City$4.2M
James McKiernanNew York$4.1M
William HuangNew York$3.9M
Jed KaminetskyMiddle Village$3.5M
Evan GoldfischerPoughkeepsie$3.1M
Gennady BratslavskySyracuse$2.5M
Ashutosh TewariNew York$2.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →